A vaccine to protect against the coronavirus will beÂ many things wrapped up in a small vial: A harbinger of a return to normalcy, a scientific feat for the ages and, depending on when it arrives, a politically potent symbol.Â Â
The timeline for how long it will take to get thatÂ vaccine is a moving target and depends on whom you ask â and when.
Dr. Anthony Fauci,Â the top infectious-disease expert at the National Institutes of Health, has repeatedly said he hopesÂ a vaccine could be available by the end of 2020 or early 2021.
President Donald Trump has promised a vaccine will be ready by the end of this year or by January. A White House-ledÂ partnership, Operation Warp Speed, has allocated almost $10 billion to the effort and as much as $1.2 billion has already been promised on a single vaccine candidate.Â Â
Pharmaceutical giantÂ AstraZeneca has pledged to have at leastÂ 300 million doses for the United States delivered as early as October 2020 â likely even before a vaccine is approved.
In an effort to cut through some of the hyperbole and get a realistic sense of when a widely-available vaccine will be available,Â USA TODAY has created a panel of nationally known experts in medicine, virology, immunology, logistics and supply chain issues to estimateÂ how far we are from a widely available coronavirus vaccine. Every month, these experts will track progress and highlight inevitable setbacks.
If you think of it as a clock ticking from midnight (when the pandemic began) to noon (when vaccines will be widely available in the United States and life returns to something approaching normal), then as of June, the panel says itâs about 4 AM.
âThe sun has not yet peeked over the horizon, but the horizon glows in the east. We are no longer in darkness,â said Dr. Kelly Moore, associate director of immunization education with the Immunization Action Coalition.
The USA TODAY vaccine panel is designed to offer readers an objective, nonpartisan understanding of how close we are to getting an effective vaccine distributed to the nationâs residents. Weâre about a third of the way there, they say.
âI think weâll have a vaccine by the middle of next year,â said Paul Offit, director of the Vaccine Education Center at Childrenâs Hospital in Philadelphia.
Pamala Bjorkman, a structural biologist at Caltech University agrees, though she believes one of the hardest parts â scaling up to make enough doses of the vaccines â is still a major challenge ahead.
âI subtracted an hour from the one-third of the way there estimate to account for manufacturability and distribution issues,â she said via email.
The challenge isnât just to create a safe and effective new vaccine â more than 11 possible candidates will be in human testing this summer. But for a vaccine to end up in a pharmacy or doctorâs office near you, companies will have to produce hundreds of millions of doses and then deliver them across the country and eventually, the world.
For June, eleven panelists answered our timeline question. Their answers fell between 2Â AM and 6Â AM, with a median of 4Â AM â the point where half of the answers were earlier and half were later.
The majority said actual progress on getting coronavirus vaccines was remarkably far along with scientists working 24/7 on ways to endÂ the pandemic.Â Â
âThe brightest minds in the world are in this fight and they are moving with an incredible sense of urgency,â said Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization, a trade group for the biotechnology industry.
In aÂ historic and global effort, the basic science behind dozens of vaccine development efforts has mostly been finishedÂ in the six months since the virus first appeared.
âThe vaccine candidates are largely in hand,â said Dr. William Schaffner, a professor of preventative medicine at Vanderbilt University.
The global effort has been stellar, said Florian Krammer, a virologist at the Icahn School of Medicine at Mount Sinai in New York City.
âI have never seen science move so fast,â he said.
While the science to come up with candidate vaccines was hard, it wasnât insurmountable given recent advances in genetics, virology and immunology.
âScience has provided cutting-edge technologies that were not possible a decade ago,â said Prakash Nagarkatti, an immunologist and vice president for research for the University of South Carolina.
Many of the vaccines in the pipeline rely on new technologies whose underlying science is understood, although the actual techniques are still being worked out.
Just having vaccine for the United States wonât protect us, saidÂ Erica Ollmann Saphire,Â a structural biologist and professor at theÂ La Jolla Institute for Immunology.Â
The important date isnât when the first person in the US can go to their doctorâs office and get the first shot. The important date is when we have enough coverage to prevent resurgence and recirculation among the human population, she said.Â
âWe have seen very clearly this year that virus anywhere can become virus everywhere,â she said.
The larger issues looming for these experts is always the messy and impossible-to-project actual outcomes: how safe and effective the vaccines will prove to be when tested in people. Chemistry is a science of formulas. Biology is the very stuff of life, and as such is almost impossible to predict.
The hardest questions to answer are still to come, they say. Will a vaccine provide lasting protection? Is it safe enough to provide to billions of people?Â Can it be produced quickly and reliably in huge quantities?
While the world is clamoring for a vaccine as quickly as possible, there can be no short-changing safety for economic or political interests, said Dr. Gregory Poland, director of the Mayo Vaccine Research Group and Editor-in-Chief of the journal Vaccine.
Especially, he said, when it comes time to license vaccines for use.
âThe Food and Drug Administration needs to demonstrate that it will not kowtow to political pressures and will do all the due diligence, safety testing and review necessary,â Poland said.
The way this work is presented to the public is crucial and the urgency has gotten in the way of emphasizing the care that goes into the process, warned Schaffner.
âWhen we say that we are âhurrying, moving fast, etc.,â what the public thinks is that we are cutting corners,â he said. âThe messaging has been unfortunate.â
The goal must be to build public confidence in whatever vaccines become available by âshowing our work openly and honestly,â said Moore. For the world to line up for shots when they become available, researchers must âbring the public along as partners in the process as we have not done perhaps since the early days of the polio vaccine.â
In the end, no estimateÂ can ever totally predict the unimaginable complexities of the bodyâs immune response to a brand new vaccine, so they remain just that, estimates. Presuming we can know the outcome is impossible.
âYou have an unusual virus, a bat coronavirus that has unusual features and weâre going to meet that with vaccine strategies that have never been tested before in large populations. âWhat,â asked Offit, âcould possibly go wrong?â
USA TODAY received responses from elevenÂ scientists and researchers, asking how far they think the vaccine development effort has progressed since Jan. 1, when the virus was first internationally recognized. Those responses were then aggregated and the median was calculated.
Pamela Bjorkman,Â structural biologist at the California Institute of Technology
Dr. Florian Krammer,Â virologist at the Icahn School of Medicine at Mount Sinai in New York City
Dr. Michelle McMurry-Heath, president and CEO of Biotechnology Innovation Organization (BIO)
Dr. Kelly Moore, associate director of Immunization Education, Immunization Action Coalition; former CDC Advisory Committee on Vaccine Practices member; chair, World Health Organization Immunization Practices Advisory Committee
Prakash Nagarkatti, immunologist, vice president for research University of South Carolina
Dr. Paul Offit, director of the Vaccine Education Center and an attending physician in the Division of Infectious Diseases at Childrenâs Hospital of Philadelphia
Dr. Greg Poland, Director, Mayo Clinicâs Vaccine Research Group,Â Editor-in-chief, Vaccine
Dan Salmon, Johns Hopkins Bloomberg School of Public HealthÂ Institute for Vaccine Safety
Erica Ollmann Saphire,Â structural biologist,Â professor at theÂ La Jolla Institute for Immunology
Dr. William Schaffner, professor of Preventive Medicine, Department of Health Policy, and professor of Medicine, Division of Infectious Diseases, Vanderbilt University
Prashant Yadav, senior fellow, Center for Global Development, medical supply chain expert
Canada's top court dismisses appeal of oil pipeline to Vancouver - KOMO News
Trump's approach to the presidency: Ignore the challenges and embrace the easy
Chat with us in Facebook Messenger. Find out what's happening in the world as it…
Chat with us in Facebook Messenger. Find out what's happening in the world as it…
(CNN) Face masks on flights have quickly become the norm as travelers tentatively return to…